SKIN CARE COMPOSITIONS CONTAINING COMBINATIONS OF COMPOUNDS FOR MIMICKING THE EFFECT ON SKIN OF RETINOIC ACID

Abstract: Compounds which sufficiently inhibit LRAT or ARAT catalyzed esterification of retinol into inactive retinyl esters, have the same effect on keratinocytes as retinoic acid. Thus, effects of retinol or retinyl esters in combination with these compounds are analogous to treatment with retinoic acid.

Description: SKIN CARE COMPOSITIONS CONTAINING COMBINATIONS OF COMPOUNDS FOR MIMICKING THE EFFECT ON SKIN OF RETINOIC ACID Field of the Invention The present invention relates to skin care compositions containing certain compounds in combination with retinol and/or retinyl ester and to cosmetic methods involving applying such compositions to the skin. Background of the Invention Retinol (vitamin A) is an endogenous compound which occurs naturally in the human body and is essential for normal epithelial cell differentiation. Natural and synthetic vitamin A derivatives have been used extensively in the treatment of a variety of skin disorders and have been used as skin repair or renewal agents. Retinoic acid has been employed to treat a variety of skin conditions, e.g., acne, wrinkles, psoriasis, age spots and discoloration. See e.g., Vahlquist, A. et al . , J. Invest . Dermatol . , Vol. 94, Holland D.B. and Cunliffe, W.J. (1990), pp. 496-498; Ellis, C.N. et al., "Pharmacology of Retinols in Skin", Vasel, Karger, Vol. 3, (1989), pp. 249-252; Lowe, N.J. et al . , "Pharmacology of Retinols in Skin", Vol. 3, (1989), pp. 240-248; PCT Patent Application No. WO 93/19743. It is believed that the use of retinol or esters of retinol would be preferred over retinoic acid. Retinol occurs naturally in the human body and is considered much safer than retinoic acid. Esters of retinol hydrolyze in-vivo to produce retinol. It is believed that retinol esters and retinol are metabolically converted in the skin into retinoic acid according to the following mechanism: Retinyl Ester Retinol i Retinoic Acid However, most of the endogenously applied retinol is rapidly converted into inactive fatty esters for storage in epidermal cells (keratinocytes) . Esterification of retinol into inactive retinyl esters is achieved in cells by transfer of a fatty acyl group from an acyl CoA, catalyzed by the enzyme acyl CoA retinol transferase (ARAT) , or by the transfer of an acyl group from phosphatidyl choline, catalyzed by the enzyme lecithin retinol acyl transferase (LRAT) . These esterification reactions are very efficient in keratinocytes-- the majority (95%) of cellular retinoids are in the form of retinyl fatty esters. Thus, unfortunately, although retinol and retinyl esters are safer to use than retinoic acid, they are less effective than retinoic acid at providing skin benefits . The present invention is based, in part, on the discovery that certain compounds inhibit these esterification reactions and thus potentiate the action of retinol by increasing the amount of retinol available for conversion to retinoic acid. Thus, a mixture of these compounds with retinol or retinyl esters mimics retinoic acid yet is safer to use than retinoic acid. Summary of the Invention The present invention includes, in part, a skin conditioning composition containing: (a) from 0.001% to 10%, by weight of the composition of retinol or retinyl ester; (b) from 0.0001% to 50%, by weight of the composition of a compound which at 100 μM concentration inhibits at least 20% of LRAT or ARAT catalyzed retinol esterification as measured by an in vitro Microsomal Assay; wherein the compound is not a fatty acid amide or dimethyl imidazolidinone; and (c) a cosmetically acceptable vehicle. Preferred compounds for use in the present invention are cyclic aliphatic unsaturated hydrocarbons, diterpenes, flavonones, flavonols, fatty hydroxyethyl imidazoline surfactants and mixtures thereof. The compounds included in the present invention in combination with retinol and/or retinyl ester are selected based on the ability of such combinations to mimic retinoic acid's effect on skin. If the compound passes an in-vitro Microsomal Assay as described herein, it is included in the present invention even if it is not explicitly mentioned herein. Put another way, if a compound inhibits sufficiently an LRAT or ARAT catalyzed retinol esterification as measured by an in-vitro Microsomal Assay, it will act in combination with retinol or retinyl ester to mimic the effect on keratinocytes (skin cells) of retinoic acid. The invention further provides a cosmetic method of conditioning skin comprising topically applying the present composition to the skin. The invention also provides a cosmetic method mimicking the effect of retinoic acid on skin, comprising topically applying the present composition to the skin. The term "conditioning" as used herein means prevention and treatment of one or more of the following: dry skin, photodamaged skin, appearance of wrinkles, age spots, aged skin. The compositions are also useful for increasing stratum corneum flexibility, lightening skin color, controlling sebum excretion and generally increasing the quality of skin. The composition may be used to improve skin desquamation and epidermal differentiation. The presence of the selected compounds in the inventive composition substantially improves the performance of retinol or retinyl ester. According to the present invention, by virtue of including an effective amount of a compound which at 100 μM concentration inhibits at least 20% of ARAT or LRAT catalyzed retinol esterification as measured by in vitro Microsomal Assay, into compositions containing retinol or a retinyl ester, the performance of the compositions is substantially improved. Description of the Preferred Embodiment The inventive compositions contain, as a first essential ingredient, a compound selected from the group consisting of retinol and retinyl ester. The term "retinol" includes amongst others the following isomers of retinol: all-trans- retinol, 13-cis-retinol, 11-cis-retinol , 9-cis-retinol , 3,4- didehydro-retinol . Preferred isomers are all-trans-retmol, 13-cis-retinol, 3 , 4-didehydro-retinol , 9-cιs-retinol . Most preferred is all-trans-retinol, due to its wide commercial availability. Retinyl ester is an ester of retinol. The term "retinol" has been defined above. Retinyl esters suitable for use in the present invention are C j -C^ esters of retinol, preferably C,-C ;o esters, and most preferably C,, C 3 , and C 16 esters because they are more commonly available. Examples of retinyl esters include but are not limited to: retinyl palmitate, retinyl formate, retinyl acetate, retinyl propionate, retinyl butyrate, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecandate, retinyl laurate, retinyl tridecanoate, retinyl myristate, retinyl pentadecanoate, retinyl heptadeconoate, retinyl stearate, retinyl isostearate, retinyl nonadecanoate, retinyl arachidonate, retinyl behenate, retinyl linoleate, retinyl oleate. The preferred ester for use in the present invention is selected from retinyl palmitate, retinyl acetate and retinyl propionate, because these are the most commercially available and therefore the cheapest. Retinyl linoleate is also preferred due to its efficacy. Retinol and/or retinyl ester is employed in the inventive composition in an amount of from 0.001% to 10%, preferably in an amount of from 0.01% to 1%, most preferably in an amount of from 0.01% to 0.5%. The second essential ingredient of the inventive compositions is a compound which passes an in vitro Microsomal Assay. A compound suitable for use in the present invention inhibits at 100 μM concentration, at least 20% of LRAT or ARAT catalyzed retinol esterification as measured by in vitro Microsomal Assay. The in vitro Microsomal Assay employed for determining the suitability of the inclusion of the compound in the inventive compositions is as follows: In a preferred embodiment of the invention, a compound is selected which, at a 100 μM concentration, inhibits at least 40% and most preferably at least 50%, of LRAT or ARAT catalyzed retinol esterification. In vitro Microsomal Assay: Microsomes are obtained as described in: J.C. Saari and D.L. Bredberg, "CoA and Non-CoA Dependent Retinol Esterification in Retinal Figment Epithelium" J. Biol . Chem. 263, 8084-90 (1988) . A solution containing 0. IM sodium phosphate pH 7 buffer, 5mM dithiothreitol, 2 mg/ml bovine serum albumin, 40 micromolar palmitoyl CoA, 40 micromolar dilauroyl phosphatidyl choline, 10 micromolar retinol and a test compound or a solvent blank, is incubated for 1 hour at 37 C with a microsomal fraction isolated from bovine retinal pigment epithelial cells. After incubation, the reaction is quenched by addition of an equal volume of ethanol, and the retinyl esters formed (retinyl laurate from the LRAT catalyzed reaction and retinyl palmitate from ARAT catalyzed reaction) are extracted with hexane. The hexane layer is removed, evaporated under nitrogen, and the residue analyzed by HPLC on a 3.9x300 mm C I9 reversed phase column using a 80% methanol in tetrahydrofuran mobile phase and fluorescence detection (325 nm excitation, 480 nm emission) to quantitate the retinyl ester. The quantity of ester formed in the presence of the solvent blank is taken as 100%, and this is used to calculate the percent inhibition of ester formation for the compounds tested. As a control, an aliquot of microsomes is inactivated by boiling for 5 minutes, which results in at least 95% inhibition of ester formation. Cyclic aliphatic unsaturated hydrocarbons, diterpenes, flavonones, flavonols and certain fatty hydroxyethyl imidazoline surfactants are examples of the compounds which satisfy the in-vitro Microsomal Assay test described above. These compounds are described individually hereinbelow. Of course, other compounds not explicitly mentioned herein are included in the inventive compositions, as long as they pass the in-vitro Microsomal Assay Test described herein. Cyclic Aliphatic Unsaturated Compounds Suitable cyclic aliphatic unsaturated compounds are selected according to the in-vitro Microsomal Assay Test described above . A preferred cyclic aliphatic unsaturated compound is selected from cyclic aliphatic unsaturated aldehydes, ketones, alcohols and esters. Preferred cyclic aliphatic unsaturated aldehydes, ketones, alcohols and esters are: alpha damascone, beta damascone, delta damascone, isodamascone, damascenone, alpha ionone, beta ionone, allyl alpha ionone, isobutyl ionone, alpha methyl ionone, gamma methyl ionone, brahmanol, sandanol, alpha terpineol, lyral, ethyl saffranate, and mixtures thereof. Structures of these compounds are as follows: α-Damascone (J-Damasconβ δ-Damascone Isodamascone 10 Damascenone alpha-Ionone beta-lonone alpha-Methyl Ionone Allyl alpha-lonone 10 Brahmanol Lyral gamma-Methyl Ionone Ethyl Saffranate Preferably, in order to maximize performance at a minimum cost, a cyclic aliphatic unsaturated compound is selected from the group consisting of damascones and ionones having the structures described above. Most preferably, the cyclic aliphatic unsaturated compound is a α-Damascone and/or α-Ionone. The cyclic aliphatic unsaturated compound can be included in the inventive compositions in an amount ranging from 0.0001% to 50% by weight of the composition, preferably it is used in an amount of from 0.01% to 10%, most preferably from 0.1% to 5%. Diterpenes Diterpenes suitable for inclusion in the present invention are those that pass the in-vitro Microsomal Assay described hereinabove. A preferred diterpene compound is geranyl geraniol, which has the following structure: Diterpene can be included in the inventive compositions in an amount ranging from 0.0001% to 50%, preferably it is used in an amount of from 0.01% to 10%, most preferably from 0.1% to 5%. Flavonones and Flavonols Flavonones and flavonols included in the present invention are those that pass in-vitro Microsomal Assay as described above. The preferred flavonones and flavonols are selected from naringenin, quercetin, and mixtures thereof. The structures of naringenin and quercetin are as follows: Naringenin Quercetin The flavonone or flavonol can be included in the inventive compositions in an amount ranging from 0.0001% to 50%, preferably it is used in an amount of from 0.01% to 10%, most preferably from 0.1% to 5%. Quercetin and/or naringenin may be obtained from Sigma. Plant extracts containing quercetin and/or naringenin are also suitable for use in the present invention, e.g. rutin, evening primrose, onion, citrus species. Fattv Hvdroxethyl imidazoline Surfactants Fatty hydroxyethyl imidazoline surfactants included in the present invention pass the m-vitro Microsomal Assay test described above. Preferred fatty hydroxyethyl imidazolmes have the following general structure: wherein R is an aliphatic saturated or unsaturated, straight or branched hydro-carbon chain containing from 8 to 20 carbon atoms . Examples of suitable fatty hydroxyethyl imidazolmes include but are not limited to cocoylhydroxyethyl imidazoline (R is derived from coconut oil fatty acids, mostly C t and some longer chain), lauryl hydroxyethyl imidazoline (R=CH (CH.) 10 ), myristyl hydroxyethyl imidazoline (R=CH 3 (CH ) > ) , stearyl hydroxyethyl imidazoline (R=CH 3 (CH 2 ) ,, ) , and oleyl hydroxyethyl imidazoline (R=CH 3 (CH 2 ) 7 CH=CH (CHJ 7 ) . Preferably, R in the fatty hydroxyethyl imidazoline contains from 8 to 18 carbon atoms, more preferably from 11 to 18 carbon atoms. Most preferably, the fatty hydroxyethyl imidazoline is oleyl hydroxyethyl imidazoline, due to its commercial availability and efficacy. The fatty hydroxyethyl imidazoline can be included in the inventive compositions in an amount ranging from 0.0001% to 50%, preferably it is used in an amount of from 0.01% to 10%, most preferably from 0.1% to 5%. Cosmeticallv Acceptable Vehicle The composition according to the invention also comprises a cosmetically acceptable vehicle to act as a dilutant, dispersant or carrier for the active ingredients in the composition, so as to facilitate their distribution when the composition is applied to the skin. Vehicles other than or in addition to water can include liquid or solid emollients, solvents, humectants, thickeners and powders. An especially preferred nonaqueous carrier is a polydimethyl siloxane and/or a polydimethyl phenyl siloxane. Silicones of this invention may be those with viscosities ranging anywhere from 10 to 10, 000 , OOOmπf's (centistokes) at 25 C. Especially desirable are mixtures of low and high viscosity silicones. These silicones are available from the General Electric Company under trademarks Vicasil, SE and SF and from the Dow Corning Company under the 200 and 550 Series. Amounts of silicone which can be utilized in the compositions of this invention range anywhere from 5% to 95%, preferably from 25% to 90% by weight of the composition. The cosmetically acceptable vehicle will usually form from 5% to 99.9%, preferably from 25% to 80% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition. Preferably, the vehicle is at least 50 wt.%, more preferably at least 80 wt.% water, by weight of the vehicle. Preferably, water comprises at least 50 wt.% of the inventive composition, most preferably from 60 to 80 wt.%, by weight of the composition. Optional Skin Benefit Materials and Cosmetic Adjuncts An oil or oily material may be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lipophilic balance (HLB) of the emulsifier employed. The inventive compositions preferably include sunscreens. Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3 , respectively. The exact amount of sunscreen employed n the emulsions can vary depending upon the degree of protection desired from the sun's UV radiation. Another preferred optional ingredient is selected from essential fatty acids (EFAs) , i.e., those fatty acids which are essential for the plasma membrane formation of all cells, in keratinocytes EFA deficiency makes cells hyperproliferative. Supplementation of EFA corrects this. EFAs also enhance lipid biosynthesis of epidermis and provide lipids for the barrier formation of the epidermis. The essential fatty acids are preferably chosen from l oleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa- (n-6, 9, 13 ) -trienoic acid, arachidonic acid, α-linolenic acid, timnodonic acid, hexaenoic acid and mixtures thereof. Emollients are often incorporated into cosmetic compositions of the present invention. Levels of such emollients may range from 0.5% to 50%, preferably between 5% and 30% by weight of the total composition. Emollients may be classified under such general chemical categories as esters, fatty acids and alcohols, polyols and hydrocarbons. Esters may be mono- or di-esters. Acceptable examples of fatty di-esters include dibutyl adipate, diethyl sebacate, diisopropyl dimerate, and dioctyl succinate. Acceptable branched chain fatty esters include 2-ethyl-hexyl myπstate, isopropyl stearate and isostearyl palmitate. Acceptable tribasic acid esters include triisopropyl trilmoleate and trilauryl citrate. Acceptable straight chain fatty esters include lauryl palmitate, myristyl lactate, oleyl eurcate and stearyl oleate. Preferred esters include coco- caprylate/caprate (a blend of coco-caprylate and coco- caprate) , propylene glycol myristyl ether acetate, diisopropyl adipate and cetyl octanoate. Suitable fatty alcohols and acids include those compounds having from 10 to 20 carbon atoms. Especially preferred are such compounds such as cetyl, myristyl, palmitic and stearyl alcohols and acids. Among the polyols which may serve as emollients are linear and branched chain alkyl polyhydroxyl compounds. For example, propylene glycol, sorbitol and glycerin are preferred. Also useful may be polymeric polyols such as poly-propylene glycol and polyethylene glycol. Butylene and propylene glycol are also especially preferred as penetration enhancers. Exemplary hydrocarbons which may serve as emollients are those having hydrocarbon chains anywhere from 12 to 30 carbon atoms. Specific examples include mineral oil, petroleum jelly, squalene and lsoparaf ins . Another category of functional ingredients within the cosmetic compositions of the present invention are thickeners. A thickener will usually be present in amounts anywhere from 0.1 to 20% by weight, preferably from 0.5% to 10% by weight of the composition. Exemplary thickeners are cross-linked polyacrylate materials available under the trademark Carbopol from the B.F. Goodrich Company. Gums may be employed such as xanthan, carrageenan, gelatin, karaya, pectin and locust bean gum. Under certain circumstances the thickening function may be accomplished by a material also serving as a silicone or emollient. For instance, silicone gums with viscosity in excess of 10 centistokes and esters such as glycerol stearate have dual functionality. Powders may be incorporated into the cosmetic composition of the invention. These powders include chalk, talc, kaolin, starch, smectite clays, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, aluminum starch octenyl succinate and mixtures thereof. Other adjunct minor components may also be incorporated into the cosmetic compositions. These ingredients may include coloring agents, opacifiers and perfumes. Amounts of these other adjunct minor components may range anywhere from 0.001% up to 20% by weight of the composition. Use of the Composition The composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening the skin, and preventing or reducing the appearance of wrinkled or aged skin. In use, a small quantity of the composition, for example from 1 to 100ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device. Product Form and Packaσinσ The topical skin treatment composition of the invention can suitably be formulated as a lotion, a cream or a gel. The composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar. The composition may also be included in capsules such as those described in U.S. Patent 5,063,057. The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined. The following specific examples further illustrate the invention. MATERIALS AND METHODS Cell Culture: Human keratinocytes, isolated from neonatal foreskin by trypsin treatment were grown in Dulbecco Modification Eagle (DME) Hams F12 (1:1) medium/10% fetal calf serum in the presence of irradiated 3T3 mouse fibroblasts for establishing dividing keratinocyte colonies. Cells were grown under the above condition until their second passage and kept frozen for future use. Frozen second passage keratinocytes were thawed and plated into the above medium and grown for five days before they were switched to a serum-free MCDB 153-based medium keratinocyte growth medium (KGM) from Clonetics Corporation, San Diego, CA, containing 0.15 mM Ca, or keratinocyte serum-free media (KSFM) from GIBCO containing 0.09 mM Ca) . On day 7, when the cells were 80-90% confluent, they were trypsinized and plated in the serum- free medium for the various experiments . Thyπύfline Assay J H-Thymidine Incorporation and Keratinocyte Proliferation The incorporation of 3 H-thymidine by cultured keratinocytes was used as an assay of keratinocyte proliferation. Thymidine is one of four deoxynucleosides which are the monomeric units of DNA, the universal library of genetic information in the animal kingdom. Prior to cell division of a somatic cell such as a keratinocyte, the complete genome of the cell undergoing cell division is replicated. This involves large scale DNA synthesis by the cell and enables both daughter cells to receive identical copies of the genetic material. When 3 H-thymidine is included in the culture media of keratinocytes which are synthesizing DNA in preparation for cell division then the labelled nucleoside is incorporated into the newly synthesized DNA. The extent of incorporation of Η-thymidine into a population of cells is proportional to the rate of DNA synthesis by this population of cells and therefore an indication of their cellular proliferation. Keratinocytes (that were cultured as described above) were plated in 24 well plates at a density of 20,000 cells per well n 1 ml media. After incubation for four days or until the cells were 60-70% confluent, the media was changed. Test compounds were added (in triplicate) to the wells 24 hours after the media change, and four hours later lμCi 3 H-Thymιdme in 50 μl media was added per well. Cells were incubated for a further 24 hours. Media was removed from the cells, 10% ice cold trichloroacetic acid (TCA) added and plates were incubated on ice for 30 minutes. Cells were washed five times with 5% TCA and allowed to dissolve in 500 μl 0. IM NaOH for at least one hour (usually overnight) . The preparations were neutralized with 0. IM HCl; 50 μl of the cell preparation was used to determine total protein content. Disintegrations per m ute (DPM) from J H labelling of DNA was determined by liquid scintillation counting of 900μl of the cell preparation. Thymidme incorporation results were expressed as DPM/μg protein. Transσlutaminase Assay Trans lutaminase Assay and Keratinocyte Differentiation During the process of terminal differentiation in the epidermis, a 15nm thick layer of protein, known as the cornif ed envelope (CE) is formed on the inner suiface of the cell periphery. The CE is composed of numerous distinct proteins which have been cross-linked together by the formation of isf- (γ-glutamyl) lysine isodipeptide bonds catalyzed by the action of at least two different transglutaminases (TGases) expressed the epidermis. Transglutaminase I (TGase I) is expressed in abundance in the differentiated layers of the epidermis, especially the granular layer, but is absent in the undifferentiated basal epidermis. Thus TGase I is a useful marker of epidermal keratinocyte differentiation with high TGase I levels indicating a more differentiated state. An ELISA based TGase I assay, using a TGase I antibody, was used to assess the state of differentiation of the cultured keratinocytes in the examples that follow. For Example 1, the following procedure was used: Keratinocytes (cultured as described above) were plated in 96 well plates at a density of 3,000 cells per well 200 μl media. After incubation for four days the media was changed to media containing test compounds (six replicates per test). The cells were cultured for a further 72 hours after which time the media was aspirated and the plates stored at -70 ° C. Plates were removed from the freezer, and the cells washed with PBS. 100 μl sterile water was added and the cells were freeze fractured by freezing at -70 C then thawing. The cells were incubated for one hour at room temperature (R/T) with PBS/3% BSA (wash buffer, bovine serum albumin) , then rinsed with a fresh aliquot of wash buffer. Cells were incubated with 50 μl of primary antibodies monoclonal anti-human transglutaminase mouse antibody (IgG) obtained from Biomedical Industries diluted 1:2,000 in wash buffer for one hour, 37 ° C then rinsed two times with wash buffer. Cells were then incubated with 50 μl of secondary antibody (Fab fragment, peroxidase conjugated anti-mouse IgG obtaining from Amersham) diluted 1:4,000 in wash buffer for one hour at 37 C, then rinsed two times with wash buffer. Cells were incubated with substrate solution (4 mg o-phenylene diam e and 3.3 μl 30% H,0 2 in 10ml 0. IM citrate buffer pH 5.0) for five minutes, R/T, in darkness (under aluminum foil) . The reaction was stopped by the addition of 50 μl 4N H 2 S0 4 . The absorbance of samples was read at 492nm in the plate reader. Out of the six replicates, four were treated with both antibodies, two were treated only with the secondary antibody (i.e., to determine background binding of enzyme conjugated Ab) . TGase levels were determined by subtracting background from the readings from each treatment and determining mean ± s.d. for the replicates exposed to both antibodies. For other Examples in which TGase I level was measured, the following procedure was used: Keratinocytes (cultured as described above) were plated in 96 well plates at a density of 3,000 cells per well in 200μl of cell culture media. After incubation for four days, the media was changed to media containing test compounds (six replicates per test) . The cells were cultured for a further 72 hours after which time the media was aspirated and the plates stored at -70 C. After the plates were removed from the freezer, the cells were further freezed fractured by freezing and thawing and then washed 3x with PBS. The cells were incubated for one hour at room temperature (R/T) with TBS/5% BSA buffer. Cells were then incubated with lOOμl of monoclonal anti-human transglutaminase (IgG) mouse antibody (primary antibody) obtained from Biomedical Technologies Inc. diluted 1:2000 m TBS/1% BSA buffer for two hours at 37 ° C, and then nnsed six times with wash buffer (TBS/1% BSA/0.05% Tween-20). Cells were next incubated with lOOμl of Fab fragment, peroxidase conjugated anti-mouse IgG antibody (secondary antibody) from Amersham diluted 1:4,000 in wash buffer for two hours at 37 C and then rinsed three times with wash buffer and three times with PBS. Cells were incubated with substrate solution (4mg o-phenylene dia ine and 3.3μl 30% H 2 0 2 in lOmL 0. IM citrate buffer, pH 5.0) for five minutes at R/T and in darkness (under aluminum foil) . The reaction was stopped by the addition of 50μl 4N H 2 S0 4 . The absorbance of samples was read at 492nm m the plate reader. Out of the six replicates, four were treated with both antibodies, two were treated only with the secondary antibody (i.e., to determine the background binding of the enzyme conjugated antibody) . Transglutaminase I levels were determined by subtracted background from the readings from each treatment and determining the mean ± s.d. for the replicates exposed to both antibodies. DNA Assay The level of TGase I detected after treatment of the cells could be influenced by cell number, i.e., the greater the number of cells the greater the level of TGase-1 detected. The level of Tgase I was normalized to DNA content of the cells in the same well thus eliminating variation due to differences in cell number. DNA quantitation is a particularly useful indicator of cell number, including keratinocyte cell number, because each cell has to all intents and purposes an identical genome and therefore an identical quantity of DNA. The total DNA content of a well of cells therefore is directly proportional to the cell number that well. Quantitation of DNA was used to normalize the TGase data to cell number. Keratinocytes were plated in 96 well plates at a density of 3,000 cells per well in 200μl media. After incubation for four days the media was changed for media containing test compounds (6 replicates per test) . The cells were cultured for a further 72 hours after which time the media was aspirated and the plates stored for at least 1.5 hours at - 70 ° C. Plates were removed from the freezer and thawed for 30 minutes. lOOμl/well of Hoechst dye (lμg/ml final concentration) was added and this was incubated for 15 minutes, covered and then read in a fluorimeter (ex. 360nm and em. 460nm) . The dye solution was removed and the wells were rinsed with PBS in preparation for the TGase assay. EXAMPLE 1 Retinoic acid is more effective than retinol at altering keratinocyte differentiation state The effect on Transglutaminase levels normalized to DNA content of the cells after addition of retinoic acid (RA) and retinol (ROH) was examined and the results are shown in Table 1. TABLE 1 3 n All concentrations of retinoic acid tested, i.e., 2.5 x 10 M, 2.5 x 10 "B M and 2.5xlO "9 M decreased keratinocyte differentiation over the ethanol control and did so to a significantly greater extent than each of the corresponding 2.5xlO "7 M, 2.5xl0 ~8 M and 2.5xlO "9 M retinol treatments. The decrease in transglutaminase level was dose dependent for both retinoic acid and retinol. This is consistent with retinoic acid having a greater inhibitory effect on epithelial differentiation than retinol. EXAMPLE 2 Method of in vitro microsomal esterification of retinol: Microsomes are obtained as described in: J.C. Saari and D.L. Bredberg, "CoA and Non-CoA Dependent Retinol Esterification in Retinal Pigment Epithelium" J. Biol . Chem. 23, 8084-90 (1988). A solution containing 0. IM sodium phosphate pH 7 buffer, 5mM dithiothreitol, 2 mg/ml bovine serum albumin, 40 micromolar palmitoyl CoA, 40 micromolar dilauroyl phosphatidyl choline, 10 micromolar retinol and a test compound or solvent blank, was incubated for 1 hour at 37 C with a microsomal fraction isolated from bovine retinal pigment epithelial cells. After incubation, the reaction was quenched by addition of an equal volume of ethanol, and the retinyl esters formed (retinyl palmitate from the ARAT catalyzed reaction, and retinyl laurate from the LRAT catalyzed reaction) were extracted with hexane. The hexane layer was removed, evaporated under nitrogen, and the residue analyzed by HPLC on a 3.9x300 mm C18 reversed phase column using a 80% methanol in tetrahydrofuran mobile phase and fluorescence detection (325 nm excitation, 480 nm emission) to quantitate the retinyl esters. The quantity of ester formed in the presence of the solvent blank was taken as 100%, and this was used to calculate the percent inhibition of ester formation for the compounds tested. As a control, an aliquot of microsomes was inactivated by boiling for 5 minutes, which resulted in at least 95% inhibition of ester formation. The results that were obtained are summarized in Table 2. COMPOUND . ARAT % INHIB. LRAT 5 oleyl hydroxyethyl imidazoline 95 oleyl hydroxyethyl imidazoline 28 caprylic hydroxyethyl imidazoline 8 diazolidinyl urea 0 10 thiamine 0 h caffeine 0 CD adenine 0 phenyl benzimidazole sulfonic acid 0 uracil 0 15 tryptophan 0 cocoglutamate 0 dimethyl cocamine oxide 0 disodium cocamphodiacetate 0 oleamidopropyl betaine 0 20 oleamine oxide 0 lauroyl sarcosine 0 It can be seen that the hydroxyethyl imidazoline surfactant is a potent esterification inhibitor, while other surfactants and other heterocyclic compounds were essentially inactive. Caprylic hydroxyethyl imidazoline (R=CH 3 (CHJ did not sufficiently inhibit LRAT. EXAMPLE 3 Example 2 was repeated with various hydroxyethyl imidazoline surfactants, having R groups as indicated in Table 3. The results that were obtained are summarized in Table 3. TABLE 3 The results in Table 3 show relative activity oleyl>coco>lauryl . Coco is better probably because it is not purely C 12 , but has some longer chain alkyl groups as well. The data in Table 2 on caprylic hydroxyethyl imidazoline showed only 8% inhibition at 100 micromolar. Taken together the data clearly shows relative activity oleyl>coco>lauryl>>caprylic . EXAMPLE 4 Transglutaminase Assay was conducted using oleyl hydroxyethyl imidazoline (OHI) , retinoic acid (RA) , retinol (ROH), and retinyl palmitate (RP) . The results that were obtained are summarized in Table 4 TABLE 4 Eχp# Compound ( s ) % of Control 1 RA 35.1 1 ROH 76.2 1 OHI 80.7 1 ROH+OHI 45.1 2 RA 43, 4 2 ROH 91. .6 2 OHI 78. 2 2 ROH+OHI 57, 9 3 RA 45. .9 3 RP 91, 6 3 OHI 91, 1 3 RP+OHI 71, 6 It can be seen from the results in Table 4 that retinoic acid substantially decreased keratinocyte differentiation whereas retinol, oleyl hydroxyethyl imidazoline, and retinyl palmitate did not affect keratinocyte differentiation when used alone, or did so to a much smaller degree than retinoic acid. In experiments 1 and 2, when retinol was combined with oleyl hydroxyethyl imidazoline, the result was a synergistic decrease in keratinocyte differentiation, to levels approaching the effect of retinoic acid. In experiment 3, when oleyl hydroxyethyl imidazoline was combined with retinyl palmitate, the result was not as dramatic as in experiments 1 and 2, but nevertheless a synergistic decrease was observed. This example also confirms that a compound which passed the in-vitro Microsomal Assay described herein, actually had an effect on keratinocytes when combined with retinol at a level similar to the effect of retinoic acid. EXAMPLE 5 The in vitro Microsomal Assay Test was run on the compounds listed in Tables 5A and 5B. The compounds in Table 5A were tested at a lOOμM concentration. The compounds in Table 5B were tested at a lOμM concentration. TABLE 5A TABLE; 5 It can be seen from the results in Tables 5A and 5B that certain cyclic aliphatic unsaturated compounds are potent inhibitors of LRAT and ARAT catalyzed retinol esterification. COMPARATIVE EXAMPLE 6 The in-vitro Microsomal Assay test was conducted with additional cyclic aliphatic unsaturated compounds. The results that were obtained are summarized in Table 6. The compounds in Table 6 were tested at a 100 μM concentration . TABLE 6 It can be seen from the results in Table 6 that not all cyclic aliphatic unsaturated compounds inhibit or sufficiently inhibit LRAT and ARAT catalyzed retinol esterification. EXAMPLE 7 The effect on keratinocyte differentiation of compounds and combinations listed in Table 7 was examined. The results were expressed as % of control. Transglutaminase level was normalized to DNA. Data are from two experiments where the retinol concentration was changed. The results that were obtained are summarized in Table 7. TABLE 7 The results in Table 7 show that while α-Damascone alone and retinol alone were not very effective, the combination of the two attained synergistic reduction in transglutaminase mimicking the effect of retinoic acid on keratinocyte differentiation. This example also establishes a good correlation between the Microsomal Assay and cell culture data. EXAMPLE 8 The in-vitro Microsomal Assay test was conducted with a diterpene compound, geranyl geraniol or farnesol . The results that were obtained are summarized in Table £ A LE 8 Obtained from TCI America (Portland, Oregon) . Also available from Sigma and CTC Organics (Atlanta, Georgia) Available from Givaudan Co. Bedoukian Co., or Dragoco Co. It can be seen from the results in Table 8 that both geranyl geraniol and farnesol inhibit retinol esterification . Geranyl geraniol is a substantially more potent esterification inhibitor, than farnesol, the structure for which is as follows: EXAMPLE 9 3 H-Thymidine incorporation was measured according to the procedure described in Materials and Methods section above. The results that were obtained are summarized in Tables 9A and 9B. TABLE 9A TABLE 9B It can be seen from the results above that geranyl geraniol is able to significantly increase the proliferation enhancing effect of retinol to a level similar to that which can be achieved with a comparable amount of retinoic acid. Again, a good correlation is proven to exist between the Microsomal Assay test and the effect of a compound on cell culture. EXAMPLE 10 The in-vitro Microsomal Assay was conducted on compounds listed in Table 10. The results that were obtained are summarized in Table 10. The compounds in Table 10 were tested at 100 μM concentration. TABLE 10 EXAMPLE 11 Narinσenin and Retinol Svner istically Inhibit Keratinocyte Differentiation The effect on TGase I levels normalised to DNA content of the cells was examined in response to a 72 hour treatment with the test compounds. The results are shown in Table 11. Naringenin was obtained from Sigma. TABLE 11 Effect of Retinol and Naringenin on Keratinocyte TGase/DNA n = 3 It can be seen from the results in Table 11 that 2.5xl0 "7 M retinoic acid was very effective at repressing keratinocyte TGase I levels (to 42% of control level). 2.5x10 ""' M retinol was ineffective (91%) and 10 "7 M naringenin had no inhibitory effect on the keratinocyte TGase I level when used alone. However, 2.5xlO ~9 M retinol + 10 "7 M naringenin repressed keratinocyte TGase I to 53% of control levels. Naringenin and retinol therefore acted synergistically to repress keratinocyte differentiation in an analogous manner to the effect of retinoic acid. EXAMPLE 12 Narinσenin and Retinyl Palmitate Svnerσisticallv Inhibit Keratinocyte Differentiation The effect on TGase I levels normalised to DNA content of the cells was examined in response to a 72 hour treatment with the test compounds. The results are shown in Table 12. TABLE 12 Effect of Retinyl Palmitate and Naringenin on Keratinocyte TGase/DNA o c CD CO -I m o x m m H c r m ro n = 3 10 It can be seen from the results in Table 12 that 2.5χlO "7 M retinoic acid was very effective at repressing keratinocyte TGase I levels (to 32% of control level). 2.5x10 5 M retinyl palmitate was ineffective (93%) and 10 "8 M naringenin had a small inhibitory effect on the keratinocyte TGase I level when used alone. However, 2.5xl0 "8 M retinol + 10 "M naringenin repressed keratinocyte TGase I to 85% of control levels. Naringenin and retinyl palmitate therefore act synergistically to repress keratinocyte differentia ion in an analogous manner to the effect of retinoic acid. EXAMPLE 13 Quercetin and Retinol Synergistically Inhibit Keratinocyte Differentia ion The effect on TGase I levels normalised to DNA content of the cells was examined in response to a 72 hour treatment with the test compounds. The results are shown in Table 13. Quercetin was obtained from Sigma. It can be seen from the results Table 13 that 2.5x10 7 M retmoic acid was effective at repressing keratinocyte TGase I levels (to 52% of control level). 2.5x10 7 M retinol was ineffective (90%) and 10 6 M quercetin had only a small inhibitory effect on the keratinocyte TGase I level when used alone. However, 2.5x10 7 M retinol + 10 6 M quercetin repressed keratinocyte TGase I to 70% of control levels. Quercetin and retinol therefore acted synergistically to repress keratinocyte differentiation in an analogous manner to the effect of ret oic acid. During the course of these studies, retmoic acid was used as positive control and reference compound against which the other compounds under analysis were compared. Retmoic acid, in a dose dependant manner decreased transglutaminase I levels in skin keratinocytes. In other words, ret oic acid decreased keratinocyte differentiation. Retinol and retinyl palmitate were significantly less effective than retinoic acid at inhibiting keratinocyte differentiation. The unexpected result demonstrated by the Examples above however was that the effect of retinol or retinyl ester on cultured keratinocytes can be enhanced to levels approaching those of ret oic acid by combining retinol or the estei with a compound which is from 0.0001% to 50% of a compound which at 100 μM concentration inhibits at least 20% of LRAT or ARAT catalyzed retinol esterification as measured by the in vitro Microsomal Assay. This effect was not only greater than the effect of either retinol or the ester or the compound itself but the two ingredients acted in synergy with each other to promote a retinoic acid-type response on the keratinocytes The results documented above demonstrate that compounds which pass the in-vitro Microsomal Assay act synergistically with retinol and retinyl esters to decrease keratinocyte differentiation and/or to increase keratinocyte proliferation, mimicking the effect on keratinocytes of retinoic acid. Examples 14-19 illustrate topical compositions according to the present invention. The compositions can be processed in conventional manner. They are suitable for cosmetic use. In particular the compositions are suitable for application to wrinkled, rough, dry, flaky, aged and/or UV-damaged skin to improve the appearance and the feel thereof as well as for application to healthy skin to prevent or retard deterioration thereof. E AMPLE 14 This example illustrates high internal phase water-m-oil emulsions incorporating the inventive composition. BΠD 92 is polyoxyethylene (2) oleyl ether EXAMPLE 15 This example illustrates oil-in-water creams according to the invention. * Brij 56 is cetyl alcohol POE (10) Alfol 16RD is cetyl alcohol EXAMPLE 16 This example illustrates alcoholic lotions according to the invention . EXAMPLE 17 This example illustrates another alcoholic lotion containing the inventive composition. EXAMPLE 18 This example illustrates a suncare cream incorporating the composition of the invention: EXAMPLE 19 This example illustrates a non-aqueous skin care composition incorporating the inventive combination. A dimethyl silicone polymer having a molecular weight of at least 50,000 and a viscosity of at least 10,000 centistokes at 25°C, available from GEC Dimethyl siloxane cyclic pentamer, available from Dow Corning Corp. 1 Dimethyl siloxane tetramer, available from Dow Corning Corp. If not mentioned in the Examples, materials employed in the present invention are obtained from the following sources: Palmitoyl CoA, BSA, dilauroylphospatidyl choline, retinol, retmoic acid dithiothreitol - from Sigma. Cyclic aliphatic unsaturated compounds: Damascones from Firmenich; Ionones from IFF; Others from suppliers in "Flavor and Fragrance Materials" 1991, by Allured Pub. Co. Imidazoline surfactants: The oleyl imidazoline was Schercozoline 0 from Scher Chemical Co.; The others were from Mclntyre, under the Mackazoline name, as follows: Caprylic, Coco, Lauryl: Mackazoline CY, C, and L, respectively.

Claims: CLAIMS 1. A skin care composition comprising: (a) from 0.001% to 10% of a compound selected from the group consisting of retinol, retinyl ester and mixtures thereof; (b) from 0.0001% to 50% of a compound which at 100 μM concentration inhibits at least 20% of LRAT or ARAT catalyzed retinol esterification as measured by an in vitro Microsomal Assay; wherein the compound is not a fatty acid amide or dimethyl imidazolidinone; and a cosmetically acceptable vehicle. 2. The composition of claim 1 wherein the compound (b) is selected from the group consisting of cyclic aliphatic unsaturated hydrocarbons, diterpenes, flavonones, flavonols, fatty hydroxyethyl imidazoline surfac ants and mixtures thereof . 3. The composition of claim 2 wherein the cyclic aliphatic unsaturated compound is selected from the group consisting of alpha damascone, beta damascone, delta damascone, isodamascone, damascenone, alpha ionone, beta ionone, allyl alpha ionone, isobutyl ionone, alpha methyl ionone, gamma methyl ionone, brahmanol, sandanol, alpha terpineol, lyral, ethyl saffranate, and mixtures thereof . 4. The composition of claim 2 or claim 3 wherein the diterpene is geranyl geraniol. 5. The composition of any one of claims 2-4 wherein the flavonone is naringenin. 6. The composition of any one of claims 2-5 wherein the flavonol is quercetin. 7. The composition of any one of claims 2-6 wherein the fatty hydroxyethyl imidazoline surfactant has the following structure: wherein R is an aliphatic saturated or unsaturated, straight or branched hydro-carbon chain containing from 8 to 20 carbon atoms. 8. The composition of any one of claims 1-7 wherein the retinyl ester is selected from the group consisting of retinyl palmitate, retinyl acetate, retinyl propionate, retinyl linoleate and mixtures thereof 9. A cosmetic method of conditioning skin the method comprising applying topically to skin a composition according to any one of claims 1-8. 10. A cosmetic method of mimicking the effect on skin of retmoic acid, the method comprising applying to the skin a composition according to any one of claims 1-8.

Inventors: BURGER ALLAN ROBERT, GRANGER STEWART PATON, IWATA KOICHI, RAWLINGS ANTHONY VINCENT, SCOTT IAN RICHARD, ZHANG KELLY HUA, BURGER, ALLAN, ROBERT, GRANGER, STEWART, PATON, IWATA, KOICHI, RAWLINGS, ANTHONY, VINCENT, SCOTT, IAN, RICHARD, ZHANG, KELLY, HUA
Applicants: UNILEVER NV, UNILEVER PLC, UNILEVER N.V.
Application year: 1997
Main classification: A61K7
IPC codes: A61K8, A61K31, A61P17, A61Q5, A61Q17, A61Q19